Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality

Gut

Volumn 38, Issue 3, 1996, Pages 447-453

  Bemelmans, M H A ^a   Greve, J W M ^a   Gouma, D J ^b   Buurman, W A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Obstructive jaundice; Soluble TNF receptors (sTNFr); Tumour necrosis factor (TNF)

Indexed keywords

LACTULOSE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT OBSTRUCTION; CONTROLLED STUDY; FEMALE; INFLAMMATION; MORTALITY; NONHUMAN; OBSTRUCTIVE JAUNDICE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SURGICAL INJURY;

ANIMALS; ANTIBODIES; BIOLOGICAL MARKERS; CHOLESTASIS, EXTRAHEPATIC; FEMALE; LACTULOSE; MICE; MICE, INBRED STRAINS; POSTOPERATIVE PERIOD; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029935225     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.3.447     Document Type: Article

References (45)

1. Pain JA, Bailey ME. Experimental and clinical study of lactulose in obstructive jaundice. Br J Surg 1986; 73: 775-8.
2. Van Bossuyt H, Desmaretz C, Gaeta GB, Wisse E. The role of bile acids in the development of endotoxemia during obstructive jaundice in the rat. J Hepatol 1990; 10: 274-9.
3. Bemelmans MHA, Greve JW, Gouma DJ, Buurman WA. Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology 1992; 15: 1132-6.
4. Bemelmans MHA, Gouma DJ, Greve JW, Buurman WA. The effect of anti-TNF treatment on circulating tumor necrosis factor and mortality after surgery in jaundiced mice. Br J Surg 1993; 80: 1055-8.
5. Greve JW, Gouma DJ, van Leeuwen PAM, Buurman WA. Lactulose inhibits endotoxin induced tumour necrosis factor production by monocytes. An in vitro study. Gut 1990; 31: 198-203.
6. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-71.
7. Greve JW, Maessen JG, Tiebosch T, Buurman WA, Gouma DJ. Prevention of postoperative complications in jaundiced rats. Ann Surg 1991; 212: 221-7.
8. Millar AB, Singer M, Meager A, Foley NM, Johnson NMcI, Rook GAW. Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndroms. Lancet 1989; ii: 712-4.
9. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i: 355-7.
10. Munck-Petersen C, Møller BK. Immunological reactivity and bioactivity of tumour necrosis factor. Lancet 1988; i: 934-5.
11. Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor (TNF) clearance in a murine model. J Immunol 1993; 150: 2007-17.
12. Engelmann H, Holtmann H, Brakebush C, Avni YS, Sarov I, Nophar Y, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990; 265: 14497-504.
13. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990; 265: 1531-6.
14. Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 3127-31.
15. Peetre C, Thysell H, Grubb A, Olsson I. A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 1988; 41: 414-9.
16. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 1992; 90: 533-6.
17. Bemelmans MHA, Gouma DJ, Buurman WA. LPS induced sTNFr-receptor release in vivo in a murine model: investigation of the role of TNF, IL-1, LIF and IFNγ. J Immunol 1993; 151: 5554-62.
18. Aderka D, Engelmann H, Maor Y, Brakebush C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-9.
19. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35: 1160-9.
20. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci 1992; 89: 4845-9.
21. Sheehan KCF, Ruddle NH, Schreiber RD. Generation and characterisation of hamster monoclonal antibodies that neutralizes murine tumor necrosis factors. J Immunol 1989; 142: 3884-93.
22. Pinto M, Kaplun A. Immune status in mice with experimental biliary obstruction. Clin Immunol Immunopathol 1980; 16: 396-405.
23. Derwent Publications Ltd. 1991: Europaische Patentanmeldung, Veröffentlichungsnummer: 0432309A1. Anmeldungsnummer: 89123301.7.
24. Dentener MA, Greve JW, Maessen JW, Buurman WA. Role of tumor necrosis factor in the phenomenon of the enhanced sensitivity of animals to endotoxin after exposure to lead. Immunopharmacol Immunotoxicol 1989; 11: 321-4.
25. Rollinghoff M, Warner NL. Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells. Proc Soc Exp Biol Med 1973; 144: 813-8.
26. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986; 95: 99-105.
27. Hanssen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119:203-10.
28. Selkurt EE. Measurement of renal blood flow. Meth Med Res 1948; 1: 191-9.
29. Dejong CHC, Kampman MT, Deutz NEP, Soeters PB. Altered glutamine metabolism in rat portal drained viscera and hindquarter during hyperammonemia. Gastroenterology 1992; 102: 936-48.
30. Rose BD. Clinical physiology of acid-base and electrolyte disorders. Tokyo: McGraw-Hill Kogakusha, 1977: 548.
31. Norusis MJ, ed. SPSS/PC+ V3.1 Base manual for the IBM PC/XT/AT and PS/2. SPSS Inc, Chicago, USA.
32. Wait RB, Kahng KU. Renal failure complicating obstructive jaundice. Am J Surg 1989; 157: 256-63.
33. Pitt HA, Cameron JL, Postier RG, Gadacz TR. Factors affecting mortality in biliary tract surgery. Am J Surg 1981; 141: 66-72.
34. Hishida A, Honda N, Sudo M, Nagase M. Mechanisms of altered renal perfusion in the early stage of obstructive jaundice. Kidney Int 1980; 1: 223-30.
35. Maessen JG, Greve JW, Buurman WA. Increased sensitivity to endotoxemia by tissue necrosis. Surgery 1991; 109: 154-9.
36. Froon AHM, Bemelmans MHA, Greve JW, van der Linden CJ, Buurman WA. Increased levels of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine. Crit Care Med 1994; 22: 803-9.
37. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85.
38. Bemelmans MHA, Gouma DJ, Buurman WA. Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine 1994; 6: 609-15.
39. Better OS, Massry SG. Effect of chronic bile duct obstruction on renal handling of salt and water. J Clin Invest 1975; 51: 402-11.
40. Clements WDB, Halliday MI, McCaigue MD, Barclay RG, Rowlands BJ. Effects of extrahepatic obstructive jaundice on Kupffer cell clearance capacity. Arch Surg 1993; 128: 200-5.
41. Tanaka N, Ryden S, Bergqvist L, Christensen P, Bengmark S. Reticuloendothelial function in rats with obstructive jaundice. Br J Surg 1985; 72: 946-9.
42. Holman JM, Rikkers LF. Biliary obstruction and host defense failure. J Surg Res 1982; 32: 208-13.
43. Dixon JM, Armstrong CP, Duffy SW, Davies GC. Factors affecting morbidity and mortality in biliary tract surgery. Gut 1983; 24: 845-52.
44. Hamilton G, Hofbauer S, Hamilton B. Endotoxin, TNF-alpha, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 1992; 24: 361-8.
45. Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N. Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 1992; 42: 663-7.